Moderna stock analysts project significant gains amid vaccine pipeline expansion

Financial analysts gave Moderna's stock a "Moderate Buy" rating in late 2021, saying the price could rise by 56 percent within a year. By November 2021, the company was worth around $140 billion, more than twice its value from six months earlier. In the second quarter of 2021, Moderna earned $2.78 billion in profit and delivered nearly 200 million COVID-19 vaccine doses. The company planned to produce up to three billion doses in 2022. Moderna was also working on new vaccines that combine COVID-19 and flu protection. Analysts expected vaccine sales to reach $38.7 billion in 2022. However, they warned that the stock carried higher risk for careful investors.